Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl β-cyclodextrin

AAPS PharmSciTech

Volumn 7, Issue 3, 2006, Pages

  Ramaiah Chowdary, Kora Pattabhi ^a   Srinivas, Sekuboyina Vijaya ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Celecoxib; Complexation; Dissolution rate; Hydrophilic polymers; Hydroxypropyl cyclodextrin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CELECOXIB; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; POVIDONE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; DRUG DERIVATIVE; METHYLCELLULOSE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMER; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HYDROPHILICITY; X RAY DIFFRACTION; CHEMISTRY; SOLUBILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; METHYLCELLULOSE; POLYMERS; POVIDONE; PYRAZOLES; SOLUBILITY; SULFONAMIDES; X-RAY DIFFRACTION;

EID: 33749680951     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070379     Document Type: Article

References (18)

1. Fromming KH, Szejtli J. CDs in Pharmacy. Dordrecht, The Netherlands: Kluwer Academic; 1994.
2. Duchene D, Wouessidjewe D. Pharmaceutical and medicinal applications of cyclodextrins. In: Dumitriu S, ed. Polysaccharides in Medical Applications. New York, NY: Marcel Dekker; 1996: 575-602.
3. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-2076.
4. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins, I: drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-1025.
5. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins, II: in vivo drug delivery. J Pharm Sci. 1996;85:1142-1169.
6. Martin Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033-1046.
7. Thompson DO. Cyclodextrins - enabhng excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997;14:1-104:
8. Hedges AR. Industrial applications of cyclodextrins. Chem Rev. 1998;98:2035-2044.
9. Mura P, Faucci MT, Bettinetti GP. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl β-cyclodextrin. Eur J Pharm Sci. 2001;13:187-194.
10. Geis GS. Update on clinical development with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl. 1999;28:31-37.
11. Fort J. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop. 1999;28:13-18.
12. Davies NM, Gudde TW, De Leeuw HA. Celecoxib, a new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin Pharmacother. 2001;2:139-152.
13. Moore PA, Hersh EV. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001; 132:451-456.
14. Tindall E. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. J Am Osteopath Assoc. 1999; 99:S13-S17.
15. Dougados M, Beier JM, Joichine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001;44:180-185.
16. Reddy MN, Rehana T, Ramakrishna S, Chowdhary KP, Diwan PV. β-Cyclodextrin complexes of celecoxib: molecular modeling, characterization and dissolution studies. AAPS PharmSci. 2004;6:E7.
17. Higuchi T, Connors KA. Phase-solubility techniques. In: Reilly CN, ed. Advances in Analytical Chemistry and Instrumentation. New York, NY: Wiley-Interscience; 1965:117-212.
18. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48-49.